AceCounter
contents footer
  1. HOME
  2. All KODEX ETFs
  3. Product Details

Domestic Equity Thematic

KODEX Biotech(244580)

KODEX Biotech ETF invests in stocks of FnGuide Bio Index composed of both KOSPI and KOSDAQ stocks related to biotech industry.

Last data obtained Quotes delayed at least 20 minutes. Market data provided by KOSCOM.

  • Current Price (KRW)

    8,790

  • iNAV (KRW)

    8,820

    up 57 (0.65%)

  • Trading Volume (shares)

    42,374

About Product

* as of Nov 14, 2019

Benchmark Index

FnGuide Bio Index

The FnGuide Bio Index is designed to capture the performance of stocks related to the Biotech industry. Constituents are chosen among MKF2000 Medical Industry stocks, and must satisfy market capitalization and liquidity standards.

View index information in detail

Key Facts

Basic Information - Net Assets, Benchmark Index, Gross Expense Ratio, Dividend, Benchmark Index, Base Currency, General Administrator, Trustee
Net Assets 18 (billion) Base Currency KRW
Inception Date May 13, 2016 General
Administrator
KSD
Gross Expense
Ratio
0.450%
(AP : 0.020%, Manager fee : 0.390%, Trustee Fee : 0.020%, General Administrator Fee : 0.020%)
Trustee KB Bank
Dividend Quarterly dividend distribution, only if applicable.
(Record date : last Business Day of January, April, July, and October)
Related
Documents
-
  • Carefully consider the Funds' investment objectives, risk factors, and charges and expenses before investing.
  • Collective investment schemes are not insured by the Korea Deposit Insurance Corporation.
  • The performance quoted represents past performance and does not guarantee future results.
  • Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold.
  • Current performance may be lower or higher than the performance quoted.
  • This information is not warranted to be accurate, complete, or timely.
  • Neither KOSCOM nor Samsung Asset Management is responsible for any damages or losses arising from any use of the information on this website.
  • This website is made in the Korean language, and if there shall arise any conflict between the Korean version and any translation thereof,
    including this -English translation, the Korean version shall prevail.

Samsung Asset Managementcompliance review No.2018-189 (2018.05.21)